1. Kim SD, Cho KS. Samter’s Triad: State of the Art. Clin Exp Otorhinolaryngol 2018; 11(2): 71–80, doi: 10.21053/ceo.2017.01606.
2.
Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. J Allergy Clin Immunol Pract 2017; 5(3): 537–545, doi: 10.1016/j.jaip.2016.10.021.
3.
Li KL, Lee AY, Abuzeid WM. Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management. Med Sci (Basel) 2019; 7(3): 45, doi: 10.3390/medsci7030045.
4.
Choi JH, Lee KW, Oh HB, et al. HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J Allergy Clin Immunol 2004; 113(3): 562–564.
5.
Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350(9091): 1599–1600.
6.
Choi JH, Park HS, Oh HB, et al. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet 2004; 114(4): 337–344.
7.
Kim SH, Choi JH, Park HS, et al. Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 2005; 35(5): 585–590.
8.
Park JS, Chang HS, Park CS, et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics 2005; 15(7): 483–492.
9.
Kim SH, Yang EM, Lee HN, et al. Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 2009; 64(8): 1221–1225.
10.
Kohyama K, Abe S, Kodaira K, et al. IL-13 and IL-17A gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2011; 107(6): 510–516.
11.
White AA, Stevenson DD. Aspirin-Exacerbated Respiratory Disease. N Engl J Med 2018; 379(11): 1060–1070, doi: 10.1056/NEJMra1712125.
12.
Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy 2016; 30(6): 407–413, doi: 10.2500/ajra.2016.30.4370.
13.
Bochenek G, Niz Ankowska E, Szczeklik A. Testing for aspirin hypersensitivity. Allergy 2002; 57(7): 562–565.
14.
Nizankowska E, Bestynska-Krypel A, Cmiel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15(5): 863–869.
15.
Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, et al. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 2004; 10(1): 51–56.
16.
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62(10): 1111–1118.
17.
Szczeklik A, Sanak M. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 2002; 32(3): 339–342.
18.
Kim MB, Lim GC, Park JA, et al. Computed Tomography Findings in Patients with Samter’s Triad: An Observational Study. Open Med (Wars) 2019; 14: 241–246, doi: 10.1515/med-2019-0018.
19.
George S, Nair R. Effectiveness of functional endoscopic sinus surgery in sinonasal polyposis and co-existing asthma, measured by pre- & postoperative spirometry. J Evolution Med Dent Sci 2017; 6(3): 150–154, doi: 10.14260/Jemds/2017/37.
20.
Yip J, Yao CM, Lee JM. State of the art: a systematic review of the surgical management of aspirin exacerbated respiratory disease. Am J Rhinol Allergy 2014; 28(6): 493–501, doi: 10.2500/ajra.2014.28.4103.
21.
Adappa ND, Ranasinghe VJ, Trope M, et al. Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol 2018; 8(1): 49–53, doi: 10.1002/alr.22036.
22.
Adelman J, McLean C, Shaigany K, et al. The Role of Surgery in Management of Samter’s Triad: A Systematic Review. Otolaryngol Head Neck Surg 2016; 155(2): 220–237, doi: 10.1177/0194599816640723.
23.
Bosso JV, Locke TB, Kuan EC, et al. Complete endoscopic sinus surgery followed by aspirin desensitization is associated with decreased overall corticosteroid use. Int Forum Allergy Rhinol 2020; 10(9): 1043–1048, doi: 10.1002/alr.22604.
24.
Cameli P, Perruzza M, Salvini M, et al. Omalizumab treatment in Samter’s triad: case series and review of the literature. Eur Rev Med Pharmacol Sci 2019; 23(18): 8124–8129, doi: 10.26355/eurrev_201909_19031.
25.
Yalcin AD, Uçar S, Gumuslu S, et al. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter’s syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol 2013; 35(4): 524–527, doi: 10.3109/08923973.2013.811598.
26.
Cameli P, D’Alessandro M, Bergantini L, et al. A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad. Monaldi Arch Chest Dis 2020; 90(3), doi: 10.4081/monaldi.2020.1397.
27.
Mustafa SS, Vadamalai K, Scott B, et al. Dupilumab as Add-on Therapy for Chronic Rhinosinusitis with Nasal Polyposis in Aspirin Exacerbated Respiratory Disease. Am J Rhinol Allergy 2021; 35(3): 399–407, doi: 10.1177/1945892420961969.
28.
Sethukumar P, Heywood R, Narula A. Samter’s triad with aural involvement: a novel approach to management. J Laryngol Otol 2014; 128(12): 1114–1116, doi: 10.1017/s0022215114002722.
29.
Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal out- comes of aspirin desensitization in aspirin exacerbated respira- tory disease. Otolaryngol Head Neck Surg 2014; 151: 575–581.
30.
Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57(7): 569–574, doi: 10.1136/thorax.57.7.569.
